Zanubrutinib joins the CLL treatment buffet

Affiliations

¹ Department of Haematology, Hospital Clinic, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
² Department of Haematology, Hospital Clinic, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain; Universitat de Barcelona, Barcelona, Spain. Electronic address: jdelgado@clinic.cat.

Comment

Pablo Mozas et al. Lancet Oncol. 2022 Aug.

. 2022 Aug;23(8):965-967.

doi: 10.1016/S1470-2045(22)00379-5. Epub 2022 Jul 7.

¹ Department of Haematology, Hospital Clinic, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
² Department of Haematology, Hospital Clinic, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain; Universitat de Barcelona, Barcelona, Spain. Electronic address: jdelgado@clinic.cat.

No abstract available

Conflict of interest statement

We declare no competing interests.

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Šimkovič M, Shadman M, Österborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trněný M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P. Tam CS, et al. Lancet Oncol. 2022 Aug;23(8):1031-1043. doi: 10.1016/S1470-2045(22)00293-5. Epub 2022 Jul 7. Lancet Oncol. 2022. PMID: 35810754 Clinical Trial.